Evofem Biosciences, Inc.
EVFM OTC
SEC CIK 1618835
Follow Evofem Biosciences
Weekly email: filings, results, news
Revenue, last quarter
$2.6M
−45.4% vs same quarter last year
Net income
−$11M
−518.6% vs same quarter last year
EPS, diluted
−$0.08
−700% vs same quarter last year
Operating cash flow
−$3.1M
−7.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $20.2M | $391K |
| FY24 | $19.4M | −$8.9M |
| FY23 | $18.2M | $53M |
| FY22 | $16.8M | −$76.7M |
| FY21 | $8.2M | −$205.2M |
| FY20 | $446K | −$142.3M |
| FY19 | $0 | −$80M |
| FY18 | - | −$125.7M |
| FY17 | - | −$105.3M |
| FY16 | - | −$66.7M |
| FY15 | - | −$43.2M |
| FY14 | - | −$10.8M |
| FY13 | - | −$15M |
| FY12 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 77.1% | 16.7% | 1.9% |
| FY24 | 80.2% | −39.6% | −45.8% |
| FY23 | 64.3% | −98% | 290.8% |
| FY22 | 73.8% | −499.6% | −455.5% |
| FY21 | 50.8% | −2023.3% | −2489% |
| FY20 | −4.9% | −23234.1% | −31907.8% |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$2M |
| FY24 | −$3.9M |
| FY23 | −$9M |
| FY22 | −$70.8M |
| FY21 | −$149.6M |
| FY20 | −$107.1M |
| FY19 | −$55.3M |
| FY18 | −$56.5M |
| FY17 | −$19.2M |
| FY16 | −$24.9M |
| FY15 | −$38.1M |
| FY14 | −$9.6M |
| FY13 | −$12.9M |
| FY12 | - |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | $18K |
| FY21 | - | $0 |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | $200K | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
- Evofem Biosciences
- Healthcare median
Show the numbers
| Year | Evofem Biosciences | Healthcare median |
|---|---|---|
| FY25 | 1.9% | −40.6% |
| FY24 | −45.8% | −60.7% |
| FY23 | 290.8% | −97.1% |
| FY22 | −455.5% | −128.5% |
| FY21 | −2489% | −129.2% |
| FY20 | −31907.8% | −136.5% |
| FY19 | - | −133.7% |
| FY18 | - | −173.4% |
| FY17 | - | −176.7% |
| FY16 | - | −164.8% |
| FY15 | - | −183.4% |
| FY14 | - | −133% |
| FY13 | - | −88.5% |
| FY12 | - | −87.4% |
News
No stories filed under Evofem Biosciences yet - coverage appears here as the news feed clusters it.